The global digital therapeutics market is projected to reach USD 17.7 billion by 2027 from USD 4.5 billion in 2022, at a CAGR of 31.6% during the forecast period. Increasing prevalence of chronic diseases, developments in digital therapeutics to curb growing healthcare costs and government initiatives to support the digital therapeutics are driving the market growth.
Digital therapeutics (DTx) is an emerging field of medicine that combines digital technology with evidence-based medical treatments to improve patient health outcomes. It leverages digital tools, such as mobile apps, remote monitoring, and virtual coaching, to provide personalized care and support to patients. The global digital therapeutics market is expected to grow at a healthy rate over the forecast period.
The growing demand for digital therapeutics solutions is mainly driven by the growing prevalence of chronic diseases, such as diabetes, cardiovascular diseases, and cancer, which are the leading causes of death globally. The use of digital therapeutics in the management of such conditions is expected to spur the growth of the market. Furthermore, the increasing adoption of mobile health (mHealth) solutions, such as telemedicine, is expected to fuel the growth of the digital therapeutics market.
Get a sample of the report: https://www.globenewswire.com/en/news-release/2022/11/30/2564954/0/en/At-31-6-CAGR-The-Digital-Therapeutics-Market-worth-17-7-billion-by-2027-Exclusive-Report-by-MarketsandMarkets.html
Top Lading Players: Noom, Inc (US), Teladoc Health, Inc. (US), Omada Health, Inc. (US), WellDoc, Inc (US), Pear Therapeutics, Inc. (US), CogniFit Inc (US), Ginger (US), Propeller Health (US), 2Morrow, Inc. (US), Canary Health (US), Click Therapeutics, Inc. (US), Akili, Inc. (US), Cognoa, Inc (US), Wellthy Therapeutics Pvt. Ltd. (India), Twill Inc. (US), Better Therapeutics, Inc (US), Mindstrong (US), Kaia Health (Germany), BehaVR Inc (US), Ayogo (Canada), Mindable Health GmbH (Germany), Virta Health Corp (US), Hinge Health, Inc. (US), Orexo AB (Sweden) and Freespira (US)
Some Key Highlights from the Report:
1 The global digital therapeutics market is projected to reach USD 17.7 billion by 2027 from USD 4.5 billion in 2022, at a CAGR of 31.6% during the forecast period.
- The increasing prevalence of chronic diseases and the rising demand for remote health monitoring are the major factors driving the growth of the global digital therapeutics market.
- The rising focus on preventive health care, technological advancements, and government initiatives to promote digital therapeutics are expected to create lucrative opportunities for the players operating in the global digital therapeutics market.
- The report provides an in-depth analysis of the global digital therapeutics market, with a detailed analysis of market trends, drivers, restraints, and opportunities.
- The report also provides an analysis of the competitive landscape, with profiles of the major players operating in the market.
Ask for Customize Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=51646724
Segments covered in the report:
By Sales Channel
- B2C
- Patients
- Caregivers
- B2B
- Providers
- Payers
- Employers
- Pharmaceutical Companies
- Other Buyers
By Application
- Preventive Applications
- Treatment/Care-related Applications
Regional Outlook:
- North America (U.S.A., Canada, Mexico)
- Europe (Italy, U.K., Germany, France, Rest of Europe)
- Asia Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- Latin America (Chile, Brazil, Argentina, Peru, Rest of Latin America)
- Middle East Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
Key Questions Addressed in the Report:
- What are the dominating factors that are influencing the growth of the industry?
- In the forecast period, which market segment is expected to rise the most?
- What are the risks and challenges that the industry is facing?
- In the coming years, which area is projected to dominate the market?
- Who are the major players in the market?
- What kind of strategic business plans have they made?
Make an Enquire to buy this report @ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=51646724
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
